{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT07218913","nct_id":"NCT07218913","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct07218913. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive cisplatin IV over 60 minutes on days 1-5 or 2-5 of each SOC cisplatin-based chemotherapy regimen cycle. Cycles repeat every 21 days for 3-4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI throughout the trial.","label":"Arm I (SOC cisplatin)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive cisplatin IV over 60 minutes on days 1-5 or 2-5 of each SOC cisplatin-based chemotherapy regimen cycle. Patients also receive Pedmark IV over 30 minutes, 6 hours after each SOC cisplatin infusion, on days 1-5 or 2-5 of each cycle. Cycles repeat every 21 days for 3-4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI throughout the trial.","label":"Arm II (SOC cisplatin, Pedmark)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2031-01-22","type":"ESTIMATED"},"conditions":["Hearing Loss","Metastatic Malignant Germ Cell Tumor","Metastatic Malignant Nongerminomatous Germ Cell Tumor","Metastatic Malignant Testicular Non-Seminomatous Germ Cell Tumor","Metastatic Testicular Seminoma","Stage II Testicular Cancer AJCC v8","Stage III Testicular Cancer AJCC v8"],"enrollment":{"count":44,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Audiometric Test","otherNames":["Audiometric Testing","Audiometry","Hearing Test"],"type":"PROCEDURE"},{"name":"Cisplatin","otherNames":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone's Chloride","Peyrone's Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"],"type":"DRUG"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography"],"type":"PROCEDURE"},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Sodium Thiosulfate Anhydrous","otherNames":["Disodium Thiosulfate","Sodium Thiosulfate, Anhydrous","Thiosulfuric Acid, Disodium Salt"],"type":"DRUG"}],"last_update":"2026-04-17","lead_sponsor":"City of Hope Medical Center","official_title":"Phase 1 Trial of Pedmark in Men Receiving Cisplatin for Metastatic Germ Cell Tumor","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2031-01-22","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence of clinically meaningful ototoxicity","timeFrame":"Up to 6 months post-treatment"}],"references":[],"start_date":{"date":"2026-02-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors","url":"https://clinicaltrials.gov/study/NCT07218913"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct07218913"}